​

Lexeo Therapeutics Ownership | Who Owns Lexeo Therapeutics?

OverviewForecastRevenueFinancialsChart

Lexeo Therapeutics Ownership Summary

Lexeo Therapeutics is owned by 113.27% institutional investors, 0.43% insiders. Balyasny asset management is the largest institutional shareholder, holding 12.11% of LXEO shares.

LXEO Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockLexeo Therapeutics113.27%0.43%-13.70%
SectorHealthcare Stocks 42.53%10.81%46.67%
IndustryBiotech Stocks 45.24%10.75%44.01%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Balyasny asset management4.01M12.11%$16.12M
Frazier life sciences management4.42M10.15%$29.38M
Affinity asset advisors3.87M8.88%$25.70M
Vestal point capital, lp3.25M7.46%$21.58M
Woodline partners lp2.57M5.90%$17.08M
Vanguard group2.23M5.11%$14.78M
Blackrock funding, inc. /de2.17M4.98%$14.42M
Point72 asset management1.94M4.46%$12.89M
Adar1 capital management1.53M3.52%$10.17M
Blackstone1.12M2.58%$7.47M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Affinity asset advisors3.87M2.24%$25.70M
Vestal point capital, lp3.25M0.97%$21.58M
Adar1 capital management1.53M0.96%$10.17M
Frazier life sciences management4.42M0.88%$29.38M
Silverarc capital management778.61K0.70%$5.17M
Dafna capital management358.08K0.59%$2.38M
Caxton17.33K0.50%$115.08K
Ikarian capital567.60K0.38%$3.77M
683 capital management922.66K0.32%$6.13M
Privium fund management b.v.192.36K0.23%$1.28M

Top Buyers

HolderShares% AssetsChange
Balyasny asset management4.01M0.02%4.01M
Adar1 capital management1.53M0.96%1.39M
Point72 asset management1.94M0.02%1.29M
683 capital management922.66K0.32%922.66K
Dimensional fund advisors lp912.53K0.00%865.51K

Top Sellers

HolderShares% AssetsChange
Eventide asset management---1.23M
Omega fund management---1.18M
Novo---1.12M
Ally bridge group (ny)---867.30K
Ra capital management---546.55K

New Positions

HolderShares% AssetsChangeValue
Balyasny asset management4.01M0.02%4.01M$16.12M
683 capital management922.66K0.32%922.66K$6.13M
Silverarc capital management778.61K0.70%778.61K$5.17M
Ameriprise financial166.54K0.00%166.54K$1.11B
Jane street group129.47K0.00%129.47K$859.69M

Sold Out

HolderChange
Rothschild investment-20.00
Coldstream capital management-93.00
Nelson, van denburg & campbell wealth management group-185.00
Gamma investing-245.00
Comerica bank-1.76K

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 202510820.00%49,357,57316.76%1130.70%7434.55%15-
Jun 30, 2025892.30%42,266,17654.77%1271.88%5435.00%15-34.78%
Mar 31, 2025914.60%28,007,979-3.59%841.10%42-26.32%23109.09%
Dec 31, 20248932.84%29,519,159-0.73%891.10%5913.46%1137.50%
Sep 30, 20246717.54%29,735,11411.93%891.39%5233.33%8-38.46%

Recent Insider Transactions

DateNameRoleActivityValue
Nov 18, 2025Townsend Richard Nolan Chief Executive OfficerSell$10.45K
Nov 18, 2025Adler Eric Chief Medical OfficerSell$5.70K
Nov 18, 2025See Tai Sandi Chief Development OfficerSell$3.58K
Nov 18, 2025Robertson Jenny Chief Legal OfficerSell$5.09K
Aug 18, 2025Otero Jose Manuel Chief Technical OfficerSell$6.68K

Insider Transactions Trends

DateBuySell
2025 Q4-14
2025 Q3-5
2025 Q2-4
2025 Q1-4
2024 Q413

LXEO Ownership FAQ

Who Owns Lexeo Therapeutics?

Lexeo Therapeutics shareholders are primarily institutional investors at 113.27%, followed by 0.43% insiders and -13.70% retail investors. The average institutional ownership in Lexeo Therapeutics's industry, Biotech Stocks , is 45.24%, which Lexeo Therapeutics exceeds.

Who owns the most shares of Lexeo Therapeutics?

Lexeo Therapeutics’s largest shareholders are Balyasny asset management (4.01M shares, 12.11%), Frazier life sciences management (4.42M shares, 10.15%), and Affinity asset advisors (3.87M shares, 8.88%). Together, they hold 31.14% of Lexeo Therapeutics’s total shares outstanding.

Does Blackrock own Lexeo Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Lexeo Therapeutics.

Who is Lexeo Therapeutics’s biggest shareholder by percentage of total assets invested?

Affinity asset advisors is Lexeo Therapeutics’s biggest shareholder by percentage of total assets invested, with 2.24% of its assets in 3.87M Lexeo Therapeutics shares, valued at 25.7M$.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools